Safety and Efficacy of Vildagliptin 100mg SR- Ft. Prof. Dr Aravinda Jagadeesha

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-12-15 05:47 GMT | Update On 2023-05-03 07:27 GMT

Among the gliptins, vildagliptin is the only therapy requiring twice-daily dosing and thus adversely impacts patient adherence. To reduce dosing frequency, a once-daily sustained-release (SR) vildagliptin 100 mg tablet formulation was developed with the potential to furnish comparable dipeptidyl peptidase-4 (DPP-4) inhibition coverage to the conventional twice-daily regimen.

Vildagliptin works by increasing the release of insulin from the pancreas and decreasing the hormones that raise blood sugar levels. This reduces fasting and post-meal sugar levels.

This diabetes drug has established its usefulness over the years by displaying significant HbA1c lowering accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy as well as newer formulations like a sustained release. Several studies have also focussed on establishing the safety parameters of Vildagliptin.

In this video, Prof. Dr Aravinda Jagadeesha, a diabetologist and the chairman at Dr Aravind's Diabetes Centre in Bengaluru, India talks about the safety and efficacy profile of Vildagliptin 100mg SR.

Vildagliptin is now present in different therapeutic doses and formulations which makes it compliant in treatment algorithms. Vildagliptin 100mg sustained release formulation, which is bioequivalent to Vildagliptin 50 mg BID, also displays similar efficacy and safety as the BID formulation.

Safety parameters of vildagliptin at all doses have been well-studied and well-documented, notes Dr Aravinda Jagadeesha.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings

2025-10-13 07:00 GMT

Safety and Efficacy of Vildagliptin 100mg SR- Ft. Prof. Dr Aravinda Jagadeesha

Similar News

DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings

How PM2.5 Pollutants Reprogram Brown Fat and Raise Diabetes Risk? Study Provides Insights

This Rare Gene Mutation May Be Linked to Diabetes in Babies Under Six Months: Study Suggests

What's Putting India at Risk for Diabetes and Obesity? ICMR Study Reveals the Hidden Dietary Culprit

Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

Mango Consumption Linked to Improved Metabolic Health and Diabetes Prevention: Study

The Silent Killer in MASLD? It's Not Diabetes, Says New Study

Study Reveals Why Some People with Obesity Avoid Disease Through Genetic Mapping